ClinicalTrials.gg
CompletedNCT05519215Updated Jan 12, 2026

A Study of ECHELON 3000 (Next Generation Powered Stapler) in General Abdominal and Thoracic Lung Resection Procedures

An observational study in Laparoscopic Sleeve Gastrectomy (LSG) and Thoracic Lung Resection Procedure, sponsored by Ethicon Endo-Surgery. Completed at 8 sites in United States. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Ethicon Endo-Surgery (part of Johnson & Johnson) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
244
Sex
All
01

Study summary

The purpose of this study is to assess the safety and performance of the ECHELON 3000 Stapler (next generation powered stapler) and reload system in participants undergoing laparoscopic sleeve gastrectomy or lung resection procedures (Video-Assisted Thoracoscopic [ATS] or open approach).

02

Conditions studied

  • Laparoscopic Sleeve Gastrectomy (LSG)
  • Thoracic Lung Resection Procedure
03

In context

Lead sponsor

Ethicon Endo-Surgery is the lead sponsor of 47 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants who plan to have a laparoscopic sleeve gastrectomy (LSG) or lung resection surgical procedure will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult and pediatric participants satisfying the following criteria will be considered eligible for enrollment in this study (procedures may be performed with or without a robot): Primary procedure where the ECHELON 3000 Stapler and reload system is planned to be used for tissue transection per the instructions for use (IFU) in either of the following, a) Laparoscopic Sleeve Gastrectomy; b) Lung resection procedures (VATS or open)
  • Adult participants- Willingness to give consent and comply with all study-related evaluations and visit schedule
  • Pediatric participants- The participant's parent/legal guardian must be willing to give permission for the participant to participate in the study and provide documented for the participants. In addition, assent must be obtained from pediatric participant who possess the intellectual and emotional ability to comprehend the concepts involved in the study. If the pediatric participant is not able to provide assent (due to age, maturity and/or inability to intellectually and/or emotionally comprehend the study), the parent/legal guardian's documented informed consent for the participant will be acceptable for the participant to be included in the study

Exclusion criteria

Exclusion Criteria:

  • Physical or psychological condition which would impair study participation
  • Procedure is a revision/reoperation for the same indication or same anatomical location
  • A procedure where surgical stapling is
  • Concurrent treatment with medications that the investigator deems could have influence on wound healing
  • Enrollment in a concurrent interventional clinical study that could impact the study endpoints
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
244 participants (actual)
Patient registry
No

Groups and cohorts

  • ECHELON 3000 Stapler

    This prospective study will include the participants who plan to have a laparoscopic sleeve gastrectomy (LSG) or lung resection surgical procedure and collect clinical data in a post-market setting. Investigators will perform each procedure using the device in compliance with their standard surgical approach and the ECHELON 3000 Stapler and reloads instructions for use (IFU).

    Device: ECHELON 3000 Stapler

Interventions

  • DeviceECHELON 3000 Stapler

    There is no intervention, beyond necessary clinical care, in this study. Echelon 3000 Stapler is used for transection and resection in LSG or lung surgical procedure per its IFU.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Select Device-related Serious Adverse Events (SAEs)

    An adverse event (AE) is defined as any untoward medical occurrence, regardless of its relationship to study device or study procedure. An untoward medical occurrence includes any new, undesirable medical experience or worsening of pre-existing condition, which occurs throughout the duration of the clinical study. SAE is defined as an AE that results in any of the following: death; a life-threatening illness or injury; a permanent impairment of a body structure or body function; hospitalization or prolongation of existing hospitalization; medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or body function; chronic disease; fetal distress, fetal death, or a congenital physical or mental impairment or birth defect. The device-related SAEs that will be captured are infection or symptoms of infection, bleeding, gastric leak (laparoscopic sleeve gastrectomy \[LSG\] only), and postoperative air leak (lung resection only).

    Time frame: 30 days post procedure

Secondary outcomes

  1. Number of Participants with All Device-related, Procedure-related Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence, regardless of its relationship to the study device or the study procedure. An untoward medical occurrence includes any new, undesirable medical experience or worsening of a pre-existing condition, which occurs throughout the duration of the clinical study.

    Time frame: 30 days post-procedure

  2. Number of Participants with All Device-related, Procedure-related SAEs

    An AE is defined as any untoward medical occurrence, regardless of its relationship to the study device or the study procedure. An untoward medical occurrence includes any new, undesirable medical experience or worsening of a pre-existing condition, which occurs throughout the duration of the clinical study. A SAE is defined as an AE that results in any of the following: death; a life-threatening illness or injury; a permanent impairment of a body structure or a body function; hospitalization or prolongation of existing hospitalization; medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function; chronic disease; fetal distress, fetal death, or a congenital physical or mental impairment or birth defect.

    Time frame: 30 days post-procedure

07

Study locations

8 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • George Washington University Hospital
    Washington D.C., District of Columbia 20037, United States
  • Emory Cardiothoracic Surgery
    Atlanta, Georgia 30322, United States
  • Henry Ford Health Center
    Detroit, Michigan 48202, United States
  • Ascension Providence Hospital
    Southfield, Michigan 48075, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Long Island Jewish Medical Center
    New Hyde Park, New York 11040, United States
  • Bariatric Medical Institute of Texas
    San Antonio, Texas 78258, United States
08

References and documents

Publications

  • Qiu B, Yan W, Chen K, Fu X, Hu J, Gao S, Knippenberg S, Schwiers M, Kassis E, Yang T. A multi-center evaluation of a powered surgical stapler in video-assisted thoracoscopic lung resection procedures in China. J Thorac Dis. 2016 May;8(5):1007-13. doi: 10.21037/jtd.2016.03.88. PubMed 27162678 ↗
  • Fegelman E, Knippenberg S, Schwiers M, Stefanidis D, Gersin KS, Scott JD, Fernandez AZ. Evaluation of a Powered Stapler System with Gripping Surface Technology on Surgical Interventions Required During Laparoscopic Sleeve Gastrectomy. J Laparoendosc Adv Surg Tech A. 2017 May;27(5):489-494. doi: 10.1089/lap.2016.0513. Epub 2016 Dec 19. PubMed 27991838 ↗

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · innovativemedicine.jnj.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jan 2025, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2022
First posted
Aug 29, 2022
StartActual
Mar 22, 2023
Primary completionActual
Jan 8, 2025
CompletionActual
Jan 8, 2025
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05519215
Responsible party
Sponsor
First posted
Aug 29, 2022
Start date
Mar 22, 2023
Primary completion
Jan 8, 2025
Completion
Jan 8, 2025
Last update
Jan 12, 2026

Study contacts

Ethicon Endo-Surgery Clinical Trial
study director · Ethicon Endo-Surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion